echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Since 2022, single pharmacy franchise chain enterprises are receiving strong support!

    Since 2022, single pharmacy franchise chain enterprises are receiving strong support!

    • Last Update: 2022-08-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [Pharmaceutical Network Industry News] Since the beginning of this year, many places have revised the supervision and management measures of drug retail chain enterprises, supported the franchise behavior and clarified the relevant manageme.
    For example, in the "Opinions on Supporting the Development of Pharmaceutical Retail Chain Enterprises" issued by the Hebei Provincial Food and Drug Administration, it is the first time to open up chain franchising and express its support for pharmaceutical retail chain enterprises to integrate other pharmaceutical retail chain enterprises in the form of mergers, reorganizations, and franchisi.
    or single pharma.
    From May 1, the "Guangdong Province Drug Retail Chain Management Supervision and Administration Measures" was officially implement.
    It is understood that the newly promulgated "Measures" clarify the behavior and method of chain operati.
    Among them, the core and innovation of the revision of the "Measures" is to recognize the franchise behavior and incorporate the franchise stores that follow the "seven unified" management regulations into the management of retail chain stor.
    The promulgation of the "Measures" will effectively enhance the high-quality development level of the pharmaceutical chain industry, the level of drug safety assurance, and the ability to supervise drug safe.
    In addition to the strong support for single pharmacy franchise chain companies in many places, since the beginning of the year in 2022, large chain stores have also sent signals to vigorously develop franchise busine.
    At present, large-scale chains such as Ordinary People, Dashenlin, Yangtianhe, e.
    have successively launched "new policies" to attract franchise.
    For example, on May 31, at the 2021 annual shareholders meeting of Yifeng Pharmacy, the company's chairman Gao Yi said that Yifeng will focus on "mergers and acquisitions + joining" to enter key provinces and expand the national mark.
    According to Yifeng’s financial report, according to the development strategy of “regional focus and steady expansion”, the company will add 297 franchised stores in 2021 through the store expansion model of “newly opened mergers and acquisitions”, a year-on-year increase of 12
    At the end of the reporting period, the company had a total of 7,809 stores, including 932 franchise stor.
    On May 26, Dashenlin joined the company and announced that it was "entering" Sichuan, and held a joining seminar in Deyang City, Sichu.
    It is understood that in recent years, the franchise business of Dashenlin has been developing steadi.
    In 2021, 620 new franchise stores will be opened, and the cumulative number of franchise stores has reached 93The growth rate of wholesale revenue in 2021 will reach 1029%, mainly from the increase brought by the company's expansion of franchise busine.
    It is worth mentioning that, in addition to Yifeng Pharmacy and Dashenlin, other major pharmacy chain giants have also issued franchise policies, covering various aspects such as operation, capital, manpower, and technolo.

    The industry believes that this year's hot franchise boom is actually one of the manifestations of the industry's increased concentration, and it is a continuation of large-scale chain mergers and acquisitio.

    In the future, against this background, giant chains such as Common People, Dashenlin, Yifeng and Shuyu Mining will continue to deploy in franchised pharmaci.

    At the same time, the concentration of retail pharmacies is expected to further increa.

    Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.